Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

Generic Formulation

Finished Dosage Forms - Product List:

Download Brochure

Dr. Reddy’s Laboratories is a leading API supplier, with a presence in over 80 countries and a portfolio of 200+ ANDA filings and approved dossiers. Our offering goes beyond APIs and our global customers have access to high-quality dossiers and finished dosage forms.

Generics Product List
Therapy Area : Oncology
Product Name Oral Inj Strength Dossier Status Connect
Bendamustine RTU 180 mg/ 4 ml, 100 mg/ 4 ml Filed
Bortezomib 3.5 mg Filed
Cabazitaxel 60 mg/ 1.5 ml Filed
Carfilzomib 30 mg/ml, 60 mg/ml Filed
Decitabine 50 mg Filed
Eribulin 1 mg/2 ml Under Development
Fulvestrant 50 mg/ml Filed
Fosaprepitant 150 mg/ ml Filed
Liposomal Doxorubicin 20 mg/10 ml ,50 mg/25 ml Filed
Palonosetron 0.075 mg/5 ml, 0.25 mg/ 5 ml Filed
Pemetrexed 100 mg, 500 mg, 1000 mg Filed
Plerixafor 24 mg/1.2 ml Filed
Zoledronic Acid 4 mg/5 ml, 5 mg/100 ml, 4 mg/100 ml Filed
Abiraterone 250 mg Filed
Capecitabine 150 mg, 500 mg Filed
Dasatinib 20, 50, 70, 80,100 and 140 mg Filed
Enzalutamide 40 mg Under Development
Everolimus 2.5, 5, 7.5, 10 mg Under Development
Lenalidomide 2.5, 5, 10, 15, 20, 25 mg Filed
Lenvatinib 4, 10 mg Under Development
Nilotinib 150, 200 mg Under Development
Palbociclib 75, 100, 125 mg Filed
Pomalidomide 1,2,3,4 mg Filed
Fingolimod 0.5 mg Filed
Abiraterone 500 mg Under Development
Imatinib Mesylate 100 MG AND 400 MG Filed
Carmustine 100 mg/vial Filed
Venetoclax 10 mg, 50 mg and 100 mg Filed
Sorafenib 200 mg Filed
Midostaurin 25 mg Filed
Sunitinib Malate 12.5 mg, 25 mg, 37.5 mg and 50 mg Filed
Nano Paclitaxel 100mg Under Development
Axitinib 1mg, 3mg, 5mg, 7mg Under Development
Cabozantinib 20 mg, 40 mg and 60 mg Under Development
Sunitinib 12.5Mg;25Mg;37.5Mg;50Mg Filed
Tofacitinib XR Tofacitinib XR Under Development
Pazopanib 200 and 400 mg Under Development
Dimethyl Fumarate 120mg, 240mg Under Development
Nintedanib 100 mg & 150 mg Under Development
Azacitidine 100 mg Filed
Bendamustine 25, 100mg Filed
Therapy Area : Central Nervous System
Product Name Oral Inj Strength Dossier Status Connect
Glatiramer 20, 40 mg Filed
Sugammadex 100 mg/ml Filed
Pregabalin 25, 50, 75, 100, 150, 200, 225, 300 mg Filed
Therapy Area : Cardiovascular
Product Name Oral Inj Strength Dossier Status Connect
Fondaparinux 2.5, 5, 7.5, 10mg Filed
Treprostinil 1, 2.5, 5, 10mg/ml Filed
Apixaban 2.5, 5mg Filed
Dabigatran 75 , 110, 150 mg Filed
Rivaroxaban 10, 15, 20 mg Filed
Sacubitril/ Valsartan 24/26, 49/51, 97/103 mg Filed
Ticagrelor 60, 90 mg Filed
Icosapent Ethy 1 g Filed
Therapy Area : Anti-Diabetic
Product Name Oral Inj Strength Dossier Status Connect
Liraglutide 6mg/ml – 3 ml fill pen Under Development
Canagliflozin + Metformin 150 mg/1000 mg, 150 mg/500 mg, 50mg/1000 mg, 50 mg/500 mg Filed
Linagliptin 5 mg Filed
Linagliptin + Metformin 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg Filed
Semaglutide 2mg/1.5mL; 4mg/3mL Under Development
Therapy Area : Gastro-Intestinal
Product Name Oral Inj Strength Dossier Status Connect
Esomeprazole 20, 40mg Filed
Esomeprazole MG + Naproxen Na 20 mg/375 mg, 20 mg/500 mg Filed
Lansoprazole ODT 15 mg and 30 mg Filed
Therapy Area : Others
Product Name Oral Inj Strength Dossier Status Connect
Daptomycin 350, 500 mg Filed
Icatibant 30 mg base /3 ml PFS Filed
Iron Sucrose 100 mg/5 ml, 200 mg/10 ml, 50 mg/2.5 ml Filed
Sevelamer Carbonate 800 mg Filed
Valganciclovir 450 mg Filed
Isotretinoin 10mg, 20mg, 30mg and 40mg Filed
Varenicline 0.5 mg and 1 mg Filed
Ferric Carboxy Maltose 50mg/mL Under Development
Teriparatide 0.6 mg/2.4 mL (0.25 mg/mL) Under Development
Rifaximine 550mg Under Development
Amphotericin B 50mg Under Development
Mesalamine 250 and 500 mg Under Development
阿普斯特 10, 20, 30 mg Filed
Therapy Area : Oncology / Acromegaly
Product Name Oral Inj Strength Dossier Status Connect
Octerotide 10mg, 20mg & 30mg Under Development
Lanreotide 60mg/0.2mL, 90mg/0.3mL and 120mg/0.5mL Under Development
Therapy Area : Anti-Obesity
Product Name Oral Inj Strength Dossier Status Connect
Liraglutide 6mg/ml – 3 ml fill pen Under Development
Therapy Area : Immuno Suppressant
Product Name Oral Inj Strength Dossier Status Connect
Sirolimus 1 mg and 2 mg Filed
Tacrolimus 0.5 mg, 1 mg and 5 mg Filed
Therapy Area Product Name Dosage Form EU Approval Status US Approval Status
Oncology Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) Single-dose Vials Injection Under review Approved
Oncology Imatinib Mesylate Tablets 100/400 mg Tablets NA Approved
Oncology Imatinib Mesylate Capsules 50/100/400 mg Capsules Approved NA
Oncology Docetaxel Injection Concentrate and 80 mg/4 ml Injection Approved Approved
Oncology Bendamustine HCl Concentrate for Solution for Infusion 180 mg_4 ml Infusion Approved NA
Oncology Bendamustine Hydrochloride Injection 25 mg/Vial and 100 mg/Vial Injection NA Tentative Approved
Oncology Capecitabine Tablets 500 mg Tablets Approved Approved
Oncology Capecitabine Tablets 150 mg Tablets NA Approved
Oncology Fulvestrant Injection 250 mg/5 ml (50 mg/ml) Injection Approved Approved
Oncology Dasatinib 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, 140 mg Film tablet Tablets Under review Tentative Approved

Meet with our product experts in one-on-one virtual sessions

Our experts will answer your questions, provide advice, and help you understand our product better

Set Up a Meeting
Generic Formulation

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

X

Let’s discuss API sourcing

Join us at Hall - 9.1 | Booth - B48

28th-30th October 2025 Messe Frankfurt, Germany

Book a slot now